• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biotronik’s Orsiro drug-eluting stent tops Abbott’s Xience in study

August 28, 2017 By Sarah Faulkner

Biotronik's OrsiroBiotronik said today that its Orsiro drug-eluting stent beat Abbott‘s (NYSE:ABT) Xience DES in a trial comparing the target lesion failure rates of both devices.

The data, which were presented at the European Society of Cardiology’s ESC Congress and published by The Lancet, showed a 6.2% TLF rate at 12-months for patients treated with Orsiro compared to 9.6% for patients treated with Xience.

The pivotal investigational device exemption trial was designed to support an upcoming premarket approval submission, Biotronik reported.

The study enrolled 1,334 patients and treated 884 with Orsiro and 450 with Xience.

After 12 months, patients with Orsiro had a 4.6% rate of target vessel myocardial infarction, compared to 8.3% of patients treated with Xience. The study also showed a 2% rate of clinically-driven target lesion revascularization for those treated with Orsiro compared to 2.4% for those treated with Xience.

“Orsiro’s rate of TLF shows an unprecedented improvement in DES outcomes compared with a control stent that has served as a standard in interventional cardiology,” principal investigator Dr. David Kandzari said in prepared remarks. “Orsiro also notably has exceptional deliverability that is essential for PCI procedures. We believe Orsiro’s ultrathin 60 micron struts, bioresorbable polymer and proven antiproliferative drug are the key elements to its superior performance.”

“At Biotronik, we’re committed to bringing proven innovation to market because we care about positively impacting lives. The data from the Bioflow-V study is evidence of the potential for Orsiro to enter the US DES market and become the standard of care in PCI,” president Marlou Janssen added. “Where Orsiro is available around the world, hospitals, physicians and patients can confidently rely on this drug-eluting stent to deliver exceptional results.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: abbott, Biotronik

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS